ES2157344T3 - Pirrolo(2,3-d)pirimidinas y su uso. - Google Patents

Pirrolo(2,3-d)pirimidinas y su uso.

Info

Publication number
ES2157344T3
ES2157344T3 ES95932693T ES95932693T ES2157344T3 ES 2157344 T3 ES2157344 T3 ES 2157344T3 ES 95932693 T ES95932693 T ES 95932693T ES 95932693 T ES95932693 T ES 95932693T ES 2157344 T3 ES2157344 T3 ES 2157344T3
Authority
ES
Spain
Prior art keywords
pyrimidins
sub
pirrolo
src
sup
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95932693T
Other languages
English (en)
Inventor
Martin Missbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2157344T3 publication Critical patent/ES2157344T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Detergent Compositions (AREA)

Abstract

SE PRESENTAN [2,3-D]PIRIMIDINAS DE FORMULA (I), EN DONDE R{SUB,1}, R{SUB,2} Y R{SUB,3}, SON TAL Y COMO SE LOS DEFINE EN LA DESCRIPCION. DICHOS COMPUESTOS TIENEN PROPIEDADES FARMACEUTICAS UTILES, Y SON ESPECIALMENTE EFECTIVOS COMO INHIBIDORES DE LA PROTEINA TIROSINA QUINASA PP60{SUP,C-SRC}. SU FORMA DE PREPARACION ES CONOCIDA PER SE.
ES95932693T 1994-09-29 1995-09-08 Pirrolo(2,3-d)pirimidinas y su uso. Expired - Lifetime ES2157344T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH295394 1994-09-29

Publications (1)

Publication Number Publication Date
ES2157344T3 true ES2157344T3 (es) 2001-08-16

Family

ID=4245363

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95932693T Expired - Lifetime ES2157344T3 (es) 1994-09-29 1995-09-08 Pirrolo(2,3-d)pirimidinas y su uso.

Country Status (20)

Country Link
US (1) US5869485A (es)
EP (1) EP0783505B1 (es)
JP (1) JP4145955B2 (es)
KR (1) KR970706288A (es)
CN (1) CN1046731C (es)
AT (1) ATE199553T1 (es)
AU (1) AU694801B2 (es)
BR (1) BR9509048A (es)
CA (1) CA2200210A1 (es)
DE (1) DE69520282T2 (es)
DK (1) DK0783505T3 (es)
ES (1) ES2157344T3 (es)
FI (1) FI112867B (es)
GR (1) GR3035996T3 (es)
HU (1) HU222181B1 (es)
MX (1) MX9702307A (es)
NO (1) NO308108B1 (es)
NZ (1) NZ293249A (es)
PT (1) PT783505E (es)
WO (1) WO1996010028A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
SI9620103A (sl) * 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
AU3176297A (en) * 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
JP4056589B2 (ja) * 1996-07-19 2008-03-05 武田薬品工業株式会社 複素環化合物、その製造法および用途
US6211215B1 (en) * 1996-07-19 2001-04-03 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
WO1998007726A1 (en) 1996-08-23 1998-02-26 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
US6251911B1 (en) 1996-10-02 2001-06-26 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
GB9704948D0 (en) 1997-03-11 1997-04-30 Knoll Ag Therapeutic agents
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
TR199902301T2 (xx) * 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
CN1264381A (zh) * 1997-08-05 2000-08-23 辉瑞产品公司 4－氨基吡咯并(3,2－d)嘧啶作为神经肽Y受体拮抗药
JP4611524B2 (ja) * 1998-06-02 2011-01-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ピロロ［２，３ｄ］ピリミジン組成物およびその使用
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
ID29028A (id) * 1998-09-18 2001-07-26 Basf Ag Pirolopirimidina sebagai penghambat protein kinase
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
JP2003509428A (ja) 1999-09-17 2003-03-11 アボツト・ゲー・エム・ベー・ハー・ウント・コンパニー・カーゲー 治療薬としてのピラゾロピリミジン
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
AU2000240570A1 (en) * 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
US20040248906A1 (en) 2001-08-10 2004-12-09 Donato Nicholas J Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia
US6770652B2 (en) * 2001-10-18 2004-08-03 Duquesne University Of The Holy Ghost Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
DE10163991A1 (de) * 2001-12-24 2003-07-03 Merck Patent Gmbh Pyrrolo-pyrimidine
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
GB0226370D0 (en) * 2002-11-12 2002-12-18 Novartis Ag Organic compounds
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
JP2007520559A (ja) * 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
ES2365869T3 (es) * 2005-11-17 2011-10-11 OSI Pharmaceuticals, LLC COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR.
ES2545907T3 (es) * 2005-12-29 2015-09-16 Abbvie Inc. Inhibidores de proteína quinasa
TW200738725A (en) * 2006-01-25 2007-10-16 Osi Pharm Inc Unsaturated mTOR inhibitors
EP2276763A1 (en) * 2008-03-19 2011-01-26 OSI Pharmaceuticals, Inc. Mtor inhibitor salt forms
EP2358720B1 (en) * 2008-10-16 2016-03-02 The Regents of The University of California Fused ring heteroaryl kinase inhibitors
WO2010066629A2 (en) * 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
CN102596963A (zh) 2009-09-10 2012-07-18 诺瓦提斯公司 二环杂芳基的醚衍生物
WO2011064211A1 (en) 2009-11-25 2011-06-03 Novartis Ag Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
JP2013528635A (ja) 2010-06-17 2013-07-11 ノバルティス アーゲー ビフェニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
WO2011157793A1 (en) 2010-06-17 2011-12-22 Novartis Ag Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
JP2014507465A (ja) 2011-03-08 2014-03-27 ノバルティス アーゲー フルオロフェニル二環式ヘテロアリール化合物
AU2012225232B2 (en) 2011-03-09 2016-05-12 Richard G. Pestell Prostate cancer cell lines, gene signatures and uses thereof
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
JP6518585B2 (ja) 2012-05-14 2019-05-22 リチャード ジー． ペステル がんの治療のためのｃｃｒ５の修飾薬の使用
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
CN108064274A (zh) 2014-07-30 2018-05-22 耶达研究及发展有限公司 用于培养多能干细胞的培养基
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
AU2017362350B2 (en) 2016-11-18 2021-12-23 Cystic Fibrosis Foundation Pyrrolopyrimidines as CFTR potentiators
US11602534B2 (en) 2017-12-21 2023-03-14 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Pyrimidine derivative kinase inhibitors
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
EP3914698B1 (en) 2019-01-23 2024-12-11 Yeda Research and Development Co. Ltd Culture media for pluripotent stem cells
US20220372040A1 (en) * 2019-10-25 2022-11-24 Accent Therapeutics, Inc. Mettl3 modulators
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) * 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung

Also Published As

Publication number Publication date
NZ293249A (en) 1999-04-29
JPH10506624A (ja) 1998-06-30
KR970706288A (ko) 1997-11-03
PT783505E (pt) 2001-08-30
CA2200210A1 (en) 1996-04-04
CN1046731C (zh) 1999-11-24
AU694801B2 (en) 1998-07-30
EP0783505B1 (en) 2001-03-07
AU3564395A (en) 1996-04-19
JP4145955B2 (ja) 2008-09-03
NO971342D0 (no) 1997-03-21
HUT76785A (en) 1997-11-28
FI971225L (fi) 1997-05-14
DE69520282T2 (de) 2001-08-09
CN1164234A (zh) 1997-11-05
NO971342L (no) 1997-03-21
GR3035996T3 (en) 2001-09-28
DE69520282D1 (de) 2001-04-12
FI971225A0 (fi) 1997-03-24
DK0783505T3 (da) 2001-07-02
BR9509048A (pt) 1998-01-06
NO308108B1 (no) 2000-07-24
EP0783505A1 (en) 1997-07-16
ATE199553T1 (de) 2001-03-15
FI112867B (fi) 2004-01-30
HU222181B1 (hu) 2003-04-28
WO1996010028A1 (en) 1996-04-04
US5869485A (en) 1999-02-09
MX9702307A (es) 1998-04-30

Similar Documents

Publication Publication Date Title
ES2157344T3 (es) Pirrolo(2,3-d)pirimidinas y su uso.
YU49315B (sh) Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
NO980126D0 (no) Plaster-formulering for perkantal administrering av fenantyl
MX9705296A (es) Compuestos novedosos de imidazol 1,4,5-susbtituidos y el uso de los mismos para preparar composiciones para uso en terapia.
FI944729L (fi) Perhydroisoindolijohdannaiset substanssi P:n antagonisteina
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
ES2150989T3 (es) Nuevos derivados de quinoxalinadiona, su preparacion y empleo en medicamentos.
IT1269826B (it) Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
FR2686084B1 (fr) Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
BG103251A (bg) Оксадиазоли, методи за получаването им и приложението им като лекарствени средства
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
BR9603429A (pt) Derivado de 11-(fenila substituída) estra-4,9-dieno processo de preparação do mesmo composição farmacêutica e uso deste derivado
NO903088D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive diazepin-derivater.
LV12260A (lv) Piridazino [4,5-b]-hinolina-5-oksida atvasinajumi to iegusana un to izmantosana par glicina antagonistiem
BR9711586A (pt) Compostos e uso dos mesmo
BG100069A (bg) Амидинови производни,съдържащи хетероциклични групи,получаване и приложението им
IT1174474B (it) Procedimento per la preparazione di formulazione galeniche particolarmente per uso farmaceutico, dietetico, cosmetico e diagnostico
FR2769915B1 (fr) Derives d'indazole tricycliques, leur preparation et leur application en therapeutique
DE69033745D1 (de) Oberflächenaktive zusammensetzungen und verfahren
FR2733750B1 (fr) Derives de l'acide gamma-oxo-alpha-(phenylmethyl)-5,6- dihydro-4h-thieno(3,4-c)pyrrole-5-butanoique, leur preparation et leur application en therapeutique
EE9800145A (et) Fenüülamidiini derivaadid, meetodid nende valmistamiseks ja nende kasutamine arstimitena
ITMI940212A0 (it) Composizioni poliolefiniche utilizzabili per la preparazione di articoli per uso biomedicale
ES2145234T3 (es) Derivados de la diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
SE9504662D0 (sv) New compounds
IT9020020A0 (it) "n,n'-ditrimetossibenzoilpiperazine 2-sostituite, procedimento per la loro preparazione e composizioni terapeutiche che le contengono

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 783505

Country of ref document: ES